Active	Status	Sponsor type	Region	Phase	Filter
9 Active 1 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Maboudi, Heidi
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder	Recruiting	3	700	US	Troriluzole, Placebo	Biohaven Pharmaceuticals, Inc.	Obsessive-Compulsive Disorder	06/25	06/25
Pedraza, Luis
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder	Recruiting	3	700	US	Troriluzole, Placebo	Biohaven Pharmaceuticals, Inc.	Obsessive-Compulsive Disorder	06/25	06/25
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease	Completed	3	804	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	10/24	10/24
NCT05443724 / 2022-001151-16: A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia	Recruiting	2	850	Europe, US, RoW	CVL-231 30 mg, Emraclidine	Cerevel Therapeutics, LLC	Schizophrenia	02/26	02/26
Kichuk, Stephen
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder	Recruiting	3	700	US	Troriluzole, Placebo	Biohaven Pharmaceuticals, Inc.	Obsessive-Compulsive Disorder	06/25	06/25
Reyno, Yelenia
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder	Recruiting	3	700	US	Troriluzole, Placebo	Biohaven Pharmaceuticals, Inc.	Obsessive-Compulsive Disorder	06/25	06/25
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis	Terminated	2	229	Canada, US	RPT193, Placebo	RAPT Therapeutics, Inc.	Atopic Dermatitis	05/24	05/24